免疫疗法
组蛋白脱乙酰基酶
表观遗传学
医学
免疫系统
癌症免疫疗法
组蛋白
临床试验
生物
表观遗传疗法
放射治疗
癌症
癌症研究
免疫学
生物信息学
内科学
DNA甲基化
基因表达
基因
生物化学
作者
Mariarosaria Conte,Raffaele De Palma,Lucia Altucci
标识
DOI:10.1016/j.biocel.2018.03.004
摘要
In recent years, anti-tumor immunotherapy has shown promising results, and immune-oncology is now emerging as the fourth major wave in the treatment of tumors after radiotherapy, chemotherapy and molecular targeted therapy. Understanding the impact of the immune system on neoplastic cells is crucial to improve its effectiveness against cancer. The stratification of patients who might benefit from immunotherapy as well as the personalization of medicine have contributed to the discovery of new immunotherapeutic targets and molecules. In the present review, we discuss the mechanistic role of histone deacetylase inhibitors (HDACi) as potential immunomodulating agents to treat cancer. Our current understanding of the use of HDACi in combination with various immunotherapeutic approaches, such as immunomodulating agents and cancer vaccines, is also addressed. The potential clinical applications of the growing number of novel epigenetic drugs for cancer immunotherapy are widening, and some of these therapies are already in clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI